Question explored with the scientific record
Can Warm aiha be caused by vaccination? Is there a model of pathogenesis in which it can be caused?
The short version: the evidence retrieved does not contain a single study that directly tests whether vaccination can cause warm autoimmune hemolytic anemia (wAIHA). The question is unanswered by this evidence.
The evidence you provided is almost entirely off-topic. It covers treatment sequencing for established wAIHA [1], a therapeutic review of FcRn blockers [2], and multiple studies of immune checkpoint molecules in cancer [3, 4, 5, 6, 7]. None of these test whether a vaccine triggers wAIHA. The closest relevant material is the molecular mimicry research: one study shows that the SARS-CoV-2 spike protein shares short peptide sequences with human proteins [12], and another shows similar mimicry in the RSV F antigen [11]. A case report documents that an Epstein-Barr virus infection triggered transient autoantibodies through mimicry [10]. These establish a plausible mechanism — a vaccine antigen that resembles a red blood cell surface protein could, in theory, break immune tolerance and drive antibody-mediated destruction of erythrocytes. But that is a theoretical pathway, not a demonstrated one.
The evidence does not include a single case report, cohort study, or controlled trial that examines wAIHA incidence after any vaccination. There is no comparison of wAIHA rates in vaccinated versus unvaccinated populations. There is no long-term safety data on this outcome. The absence of evidence is not evidence of safety, but it is also not evidence of causation. The mechanism is plausible on first principles — molecular mimicry is documented for several vaccine antigens [11, 12], and the immune stimulation from an adjuvant could theoretically disrupt tolerance in a susceptible individual — but no study in this set confirms that it happens.
| What the evidence contains | What it does not contain |
|---|---|
| Molecular mimicry between vaccine antigens and human proteins [11, 12] | Any direct test of wAIHA after vaccination |
| Case report of infection-triggered autoantibodies via mimicry [10] | Any wAIHA incidence data in vaccinated vs unvaccinated |
| Treatment studies for established wAIHA [1, 2] | Any long-term safety study on this outcome |
My call: the evidence retrieved does not answer whether vaccination can cause wAIHA. The mechanism is plausible but unconfirmed. Confidence: not clear — the gap in the evidence is the finding.
Sources examined 12
-
Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy
A Markov-model health-economic analysis compares second-line sequencing options for adult primary warm autoimmune hemolytic anemia, finding splenectomy-then-rituximab and rituximab-then-splenectomy yield similar lifetime costs and QALYs with no clear advantage under current vacc…
DOI: 10.1182/blood-2023-189957 -
FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia
A comprehensive review of FcRn blockade as a targeted therapeutic strategy for IgG-driven autoimmune diseases, focusing on warm autoimmune hemolytic anemia (wAIHA) and the clinical development of Nipocalimab and other FcRn inhibitors, their mechanisms, trial results, safety, and…
DOI: 10.3390/antib14030065 -
Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
This study investigates the expression of immune checkpoint regulators PD-L1, PD-1, CTLA-4, and IDO in uterine mesenchymal tumors, revealing that nearly 50% of these tumors express at least one immune checkpoint, with mutually exclusive expression patterns between tumor and infi…
DOI: 10.1186/s13000-022-01251-2 -
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
This study investigates the expression of PD-1 and PD-L1 as immune checkpoint inhibitors in mantle cell lymphoma (MCL) and concludes that they do not represent relevant targets for treatment, with age potentially impacting the effectiveness of immune checkpoint inhibitors.
DOI: 10.1186/s12885-022-09803-x -
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
This study investigates the expression of immune checkpoint molecules PD-L1 and IDO1 in poorly differentiated thyroid carcinoma (PDTC) to evaluate their potential as therapeutic targets for immune checkpoint inhibitors.
DOI: 10.1007/s12022-018-9514-y -
Predicting the Efficacy of Immune Checkpoint Inhibitors in Esophageal Cancer: Changes in Peripheral Blood Lymphocyte Subsets Before and After Immunotherapy
This study investigates the predictive value of changes in peripheral blood lymphocyte subsets, particularly CD8+ T lymphocytes and NK cells, as biomarkers for the efficacy of immune checkpoint inhibitors in patients with esophageal cancer.
DOI: 10.2147/CMAR.S503171 -
Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital
This prospective observational study investigates the association between cutaneous immune-related adverse events (cirAEs) and overall survival and progression-free survival in 189 oncology patients receiving immune checkpoint inhibitors at a Spanish tertiary care hospital, find…
DOI: 10.2340/actadv.v105.42023 -
Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside
This study investigates the molecular mimicry of phage displayed peptides that mimic the GD3 ganglioside, revealing their homology to self-proteins and suggesting potential applications in melanoma immunotherapy.
DOI: 10.1016/s0196-9781(99)00095-9 -
Molecular mimicry and the generation of host defense protein diversity
This study investigates the molecular mimicry and evolutionary dynamics of host defense proteins, revealing that these proteins exhibit significantly greater divergence compared to other protein classes, potentially driven by coevolution with pathogens.
DOI: 10.1016/0092-8674(93)90571-7 -
Case report: anti-fibrillarin autoantibodies induced by viral molecular mimicry in a paediatric patient
This case report describes a 14-year-old girl who developed anti-fibrillarin autoantibodies due to molecular mimicry from an Epstein-Barr virus infection, highlighting the transient nature of such autoimmune responses in pediatric patients.
DOI: 10.1186/s13052-025-02029-0 -
Molecular Mimicry between Respiratory Syncytial Virus F Antigen and the Human Proteome
This study investigates molecular mimicry between the Respiratory Syncytial Virus F antigen and the human proteome, revealing significant peptide sharing that may contribute to autoimmunity following vaccination.
DOI: 10.1055/s-0043-1761489 -
Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine
This study investigates the molecular mimicry between the SARS-CoV-2 spike glycoprotein and mammalian proteomes, suggesting that such mimicry may contribute to the autoimmune responses observed in COVID-19 patients.
DOI: 10.1007/s12026-020-09152-6